Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China

BMC Endocrine Disorders

Table 4 Association between hyperuricemia and dyslipidemia in different clinical classification

Clinical type	β	SE	WaldX²	P	OR(95%CI)
I
Model 1	-0.348	0.017	419.613	< 0.0001	0.706(0.683–0.730)
Model 2	-0.289	0.018	273.077	< 0.0001	0.749(0.724–0.775)
Model 3	-0.258	0.018	204.343	< 0.0001	0.773(0.746–0.801)
II
Model 1	0.779	0.013	3559.724	< 0.0001	2.178(2.123–2.235)
Model 2	0.625	0.013	2189.198	< 0.0001	1.868(1.820–1.918)
Model 3	0.562	0.014	1623.596	< 0.0001	1.753(1.706–1.802)
III
Model 1	0.935	0.014	4671.861	< 0.0001	2.547(2.479–2.616)
Model 2	0.799	0.014	3234.758	< 0.0001	2.223(2.163–2.285)
Model 3	0.655	0.015	1950.771	< 0.0001	1.925(1.870–1.982)
IV
Model 1	-0.141	0.023	36.557	< 0.0001	0.868(0.829–0.909)
Model 2	-0.405	0.025	270.189	< 0.0001	0.667(0.635-0.700)
Model 3	-0.410	0.025	276.740	< 0.0001	0.663(0.632–0.696)

Notes: I: Hypercholesterolemia II: Hypertriglyceridemia III: Mixed hyperlipidemia IV: low high-density lipoprotein cholesterol (HDL) dyslipidaemia
Model 1: Unadjusted
Model 2: Adjusted for age and sex
Model 3: Adjusted for age, sex, smoking, drinking, obesity, hypertension, diabetes, ALT, AST, BUN, SCR

ISSN: 1472-6823